immatics biotechnologies GmbH is a business based in the US. immatics biotechnologies GmbH shares (IMTXW) are listed on the NASDAQ and all prices are listed in US Dollars. immatics biotechnologies GmbH employs 134 staff and has a market cap (total outstanding shares value) of 0.00.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $3.58 |
|---|---|
| 52-week range | $1.25 - $4.14 |
| 50-day moving average | $0.00 |
| Wall St. target price | N/A |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | N/A |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.58 from 2023-09-21
| 1 week (2023-09-15) | 1.99% |
|---|---|
| 1 month (2023-08-22) | -8.44% |
| 3 months (2023-06-22) | 0.28% |
| 6 months (2023-03-22) | 71.29% |
| 1 year (2022-09-22) | 66.51% |
|---|---|
| 2 years (2021-09-22) | -20.62% |
| 3 years (2020-09-22) | 32.59% |
| 5 years (2018-09-18) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | 0% |
| Return on equity TTM | 0% |
| Profit margin | -156.4% |
| Book value | N/A |
| Market Capitalization | $673 million |
TTM: trailing 12 months
We're not expecting immatics biotechnologies GmbH to pay a dividend over the next 12 months.
Immatics N. V. engages in the discovery of targets for cancer immunotherapies. It is developing targeted immunotherapies with focus on treating solid tumors through two distinct therapeutic modalities, such as Adoptive Cell Therapies and antibody-like TCR Bispecifics. Its pipeline comprises of eight therapeutic programs, of which four are in clinical trials and four are in preclinical development. The company is based in Tuebingen, Germany. .
Everything we know about the Discord IPO, plus information on how to buy in.
We’ve pulled a list together of the meme stocks being mentioned most on Reddit in the past 24 hours.
Steps to owning and managing TOTA, with 24-hour and historical pricing before you buy.
Steps to owning and managing TOT, with 24-hour and historical pricing before you buy.
Steps to owning and managing THBR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBE, with 24-hour and historical pricing before you buy.
Steps to owning and managing TEF, with 24-hour and historical pricing before you buy.
Steps to owning and managing PSACU, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNK, with 24-hour and historical pricing before you buy.
Steps to owning and managing IPHA, with 24-hour and historical pricing before you buy.